Life Sciences

  • June 11, 2026

    Chinese Biopharma Sues Over National Security Threat Label

    Chinese pharmaceutical company WuXi AppTec sued the U.S. Department of Defense on Thursday, asking a D.C. federal court to set aside the agency's designation of the company as a Chinese military company, which it said was done "without a lawful or factual basis."

  • June 11, 2026

    23andMe To Pay $46.7M To Resolve Data Breach Claims

    The plan administration trust created under the Chapter 11 plan of DNA-testing company 23andMe has struck a deal to pay $46.7 million to data breach claimants, saying the move brings 23andMe one step closer to resolving the fallout of a massive data breach in 2023.

  • June 11, 2026

    Cancer Diagnostics Firm Ignite Inks $150M SPAC Merger

    Precision oncology startup Ignite Proteomics LLC will merge with special purpose acquisition company Copley Acquisition Corp. in a deal valuing Ignite at a pro forma enterprise value of $150 million, the companies announced Thursday.

  • June 11, 2026

    Moderna Says New COVID Vax Doesn't Infringe BioNTech IP

    Moderna has pushed back at BioNTech's patent infringement lawsuit accusing its newer COVID-19 vaccine of exploiting BioNTech's own technology, saying that it never infringed and that the patent was invalid to begin with.

  • June 11, 2026

    7th Circ. Rejects Firms' Bid For More Flea Collar MDL Fees

    The Seventh Circuit on Wednesday affirmed an Illinois federal court's refusal to order a redistribution of attorney fees from a $15 million settlement resolving multidistrict litigation against Bayer and other manufacturers of Seresto flea and tick collars, saying two law firms arguing they were cut out of their fair share failed to timely challenge the fee-allocation process.

  • June 10, 2026

    DexCom Says Diabetes Tech Issue Isn't Investor Fraud

    Medical device maker DexCom Inc. has urged a New York federal judge to toss a proposed investor class action over the reliability of the company's glucose monitoring device, arguing the suit is an attempt to recast good-faith business "as fraud based on routine disagreement between a medical device company and its regulator."

  • June 10, 2026

    Catalyst Investor Sues Over Proposed $4.1B Angelini Buyout

    An investor of rare disease treatment company Catalyst Pharmaceuticals Inc. is attempting to stop a buyout by Italian rival Angelini Pharma SpA, saying Catalyst's deficient proxy statement omits relevant information regarding potential conflicts in the proposed transaction.

  • June 10, 2026

    FDA Rule For Nicotine Pouches Likely Flawed, Judge Says

    The U.S. Food and Drug Administration can't stop companies from selling ZEO Universe synthetic nicotine pouches, a Florida federal court has ruled, saying the agency likely acted illegally when it imposed costly new testing requirements without analyzing their economic effect on small businesses.

  • June 10, 2026

    PTAB Invalidates Inari Embolism Treatment Patent

    The Patent Trial and Appeal Board has invalidated the entirety of an Inari Medical Inc. patent covering the company's thrombectomy products, in a challenge brought by Imperative Care Inc.

  • June 10, 2026

    Greenberg Traurig Hires 2 IP Litigators From Goodwin Procter

    Greenberg Traurig LLP announced Wednesday that it had brought on two veteran litigators from Goodwin Procter LLP to its New York office, bolstering its intellectual property litigation practice as the law evolves to keep pace with ever-changing technological innovations.

  • June 10, 2026

    Alachua Wants DOD's $147M Chapter 11 Claim Slashed To $5M

    Biotech group Alachua Government Services asked a Delaware bankruptcy judge to trim the U.S. Department of Defense's Chapter 11 claim by $142 million, saying the government relied upon inapplicable federal regulations in claims connected to rejected contracts.

  • June 10, 2026

    Abbott Offered Faulty Health Plan Option, Ex-Worker Says

    Abbott Laboratories violated federal benefits law by offering a health plan option with higher premiums and lower deductibles without disclosing that participants would always pay less if they chose a high-deductible plan, according to a proposed class action filed Wednesday in Illinois federal court.

  • June 10, 2026

    J&J Hit With $32M Verdict In LA Baby Powder Cancer Trial

    A Los Angeles jury Tuesday awarded $32 million to the family of a woman who died of mesothelioma and who said she used Johnson's Baby Powder on herself and her children for decades, finding the product was a substantial factor in causing her illness. 

  • June 10, 2026

    AmeriHealth Unit, PBM Look To Escape Pharmacy Fee Suit

    The AmeriHealth Caritas Health Plan and its in-house pharmacy benefits manager asked a federal court to toss a proposed class action over "transmission fees," alleging the law that required disclosure of those fees, Pennsylvania's Human Services Code, doesn't let private parties sue.

  • June 10, 2026

    DC Circ. Asked To Freeze DOJ's Medical Pot Rescheduling

    A trade association for drug-testing companies and a biopharma firm developing marijuana-derived drugs have urged the D.C. Circuit to hit pause on a U.S. Department of Justice rule rescheduling state-sanctioned medical pot while their challenge to the policy change plays out.

  • June 10, 2026

    Amgen Can't Amend Petition To Address Potential Double Tax

    Drugmaker Amgen isn't entitled to amend its petition to protect against possible double taxation after an eight-week trial and briefing in its income-allocation case already have been completed, the U.S. Tax Court said, noting that the trial concluded in January 2025.

  • June 10, 2026

    $25M Patent Verdict Against Ferring Backed By Del. Court

    Swiss drugmaker Ferring Pharmaceuticals Inc. on Wednesday lost its bid to dodge a $25 million verdict in a Delaware federal court patent case over an experimental enema used to treat a particularly deadly form of diarrhea.

  • June 10, 2026

    Goodwin, Covington Lead Parabilis' $670M Upsized IPO

    Venture-backed biotechnology firm Parabilis Medicines hit the public markets Wednesday after raising $670 million in its upsized initial public offering.

  • June 10, 2026

    Insurance Cos. Score Dismissal Of Zepbound Coverage Case

    A D.C. federal judge Wednesday agreed to toss a proposed class action against CVS Caremark and CareFirst BlueCross BlueShield from a worker who challenged coverage denials for Zepbound to treat sleep apnea, holding an exclusion in his employee health plan that the companies administered complied with federal benefits law.

  • June 10, 2026

    Lab To Pay $4.9M To Settle AGs' COVID Test Pricing Suit

    Eighteen states' attorneys general have entered into a $4.87 million settlement with GS Labs to resolve claims that the defunct testing company overcharged consumers for COVID-19 tests, according to statements issued Wednesday.

  • June 10, 2026

    Acadia Pharma Must Face Investors' Drug Approval Claims

    Acadia Pharmaceuticals must face investors' class action claims it misstated the likelihood that it would get regulatory approval to market its psychosis drug pimavanserin for expanded use, a California federal judge determined, finding a key question about a regulator's directions should be decided by a jury.

  • June 10, 2026

    Conn. Woman Says Pharmacy 'Grossly' Exceeded Med Dose

    A New York compounding pharmacy injured a Connecticut woman by providing her with a medication that contained a "grossly excessive" amount of the active ingredient, as much as 91,511% of the dose on the label, according to a product liability and malpractice lawsuit.

  • June 09, 2026

    Novartis, AbbVie Lose Bid To Halt Wash. 340B Pharmacy Law

    A Washington federal judge declined Tuesday to block a state law passed to protect prescription drug access for low-income and uninsured patients, rejecting arguments from AbbVie and Novartis that the new measure illegally adds to pharmaceutical manufacturers' obligations under the federal 340B Drug Pricing Program.

  • June 09, 2026

    Morrison Foerster Brings On Sidley Patent Litigation Duo

    A pair of Sidley Austin LLP patent and trade secrets litigators, including the firm's co-leader of its global intellectual property practice, have departed for Morrison Foerster LLP, according to an announcement made Tuesday.

  • June 09, 2026

    Agensys Sues Biopharmas For Alleged Trade Secret Theft

    Agensys Inc. filed a trade secret misappropriation suit in California federal court Tuesday against a U.S.-based cancer research firm and two alleged Chinese affiliates, claiming they stole confidential information for oncology antibodies developed at Agensys and that the theft was "willful and malicious."

Expert Analysis

  • How Recent Del. Rulings Clarify M&A Deal Fraud Carveouts

    Author Photo

    Two recent Delaware decisions have provided clarity regarding when a party can or cannot rely on representations made during the course of an M&A transaction, particularly on the scope and enforceability of antireliance provisions, and on representations they knew or should have known were false, says Anthony Boccamazzo at Olshan Frome.

  • High Court's 'Skinny Label' Case May Tackle Wider Questions

    Author Photo

    The U.S. Supreme Court's upcoming decision in Hikma v. Amarin will have important ramifications for broader debates over what defines a generic version of a drug, and the pending case is already altering patent practice, say attorneys at Taft.

  • Aligning Microsoft Tools With NYC Bar AI Recording Guidance

    Author Photo

    The New York City Bar Association’s recently issued formal opinion, providing ethical guidance on artificial intelligence-assisted recording, transcription and summarization, raises immediate questions about data governance and e-discovery for companies that use Microsoft 365 and Copilot, say Staci Kaliner, Martin Tully and John Collins at Redgrave.

  • FDA's Biosimilarity Guidance Holds Uncertain Implications

    Author Photo

    The U.S. Food and Drug Administration's new draft guidance aimed at simplifying the biosimilarity demonstration process may not be enough to overcome the barriers that have historically constrained biosimilar competition, and could affect biosimilar access in unexpected ways, say analysts at Analysis Group.

  • Unpacking Key Themes From NY's New Healthcare Strategy

    Author Photo

    New York Gov. Kathy Hochul's 2026 State of the State agenda, read together with the state's fiscal year 2027 executive budget, reflect a clear framework to utilize Medicaid as the state's operating platform for healthcare reform, say attorneys at Sheppard.

  • 5 Different AI Systems Raise Distinct Privilege Issues

    Author Photo

    A New York federal court’s recent U.S. v. Heppner decision, holding that a defendant’s use of Claude was not privileged, only addressed one narrow artificial intelligence system, but lawyers must recognize that the spectrum of AI tools raises different confidentiality and privilege questions, says Heidi Nadel at HP.

  • Opinion

    AI-Assisted Arbitration Needs Safeguards To Ensure Fairness

    Author Photo

    As tribunals and arbitral institutions increasingly use artificial intelligence tools in their decision-making processes, ​​​​​​​clear disclosure standards and procedural safeguards are necessary to ensure that efficiency gains do not erode the fairness principles on which arbitration depends, says Alexander Lima at Wesco International.

  • Trans Care Enforcement Landscape Is Evolving Quickly

    Author Photo

    The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.

  • Series

    Playing Piano Makes Me A Better Lawyer

    Author Photo

    Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.

  • 3 Cases Highlight SEC Distinction Between Exec, Co. Liability

    Author Photo

    Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.